[Summary]

The present invention has a special filling (WIE) property parameter value developed using microrheology technology, and thus exhibits improved high viscoelasticity flow properties, has low mobility when injected into skin whilst still maintaining the shape thereof, and thus has excellent soft tissue restoration properties, for example for the cheeks, breasts, nose, lips or bottom, and excellent volume expansion and wrinkle alleviation properties.

The present disclosure relates to injectable compositions capable of forming a scaffold in situ at an intervertebral disc site, the composition comprising: (a) a biocompatible polymer; and (b) a biocompatible solvent system in sufficient amount to solubilize the biocompatible polymer in sufficient degree to allow injectable delivery to a disc site.

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days. The assembly further includes a fixation portion coupled to the depot and configured to facilitate attachment of the depot assembly to tissue at or adjacent to the treatment site.

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. Some of the hyaluronic acid-based compositions can include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. Compared to conventional compositions that include lidocaine, some of the hyaluronic acid-based compositions disclosed herein can have an enhanced stability, for example, when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such compositions are also provided.

An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.

AlgaeAid is an inulin-integrating hydrogel dressing aimed at the treatment of second and third-degree burns and infected chronic wounds, which lack an optimal dressing. Currently, the vast majority of dressings for burns and chronic wounds are not optimal for all kinds of wounds. AlgaeAid's implementation of inulin separates it from the rest of the antibiotic hydrogels. The inulin allows for increased water retention within a hydrogel because it becomes osmotically active when combined with a liquid. As this property allows plants to remain hydrated and withstand dry and cold temperatures, increasing water retention. The flexibility that inulin provides makes AlgaeAid more universally applicable and allows for the treatment of wounds with more fluid expulsion which makes it effective against superbugs such as MRSA and can be readily sourced from a wide variety of algae and plant sources, including chicory, algae, and 35 other plant species.

The present invention relates to a process for preparing a hydrogel, comprising the following steps: a) provision of a polysaccharide or a salt thereof; b) crosslinking of the polysaccharide in the presence of 0.05 to 10 mol %, preferentially 0.1 to 2 mol %, of at least one crosslinking agent, or a salt thereof, per 1 mol of repeat units of the polysaccharide; c) functionalisation of the polysaccharide with at least one silylated molecule of formula Chem. I or a salt thereof; d) sol-gel reaction of at least one part of the Si—OR.sup.10 groups and optionally at least one part of the SiOR.sup.4 groups of the molecule of formula Chem. I or a salt thereof when they are present.

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.

The invention concerns methods for the selective, topical or trans dermal delivery or removal of one or more substances to, or from, respectively, the skin or surface of a human or animal subject, via the topical or transdermal application of a porous, polymeric composition capable of releasing or sorbing (adsorbing and/or absorbing) said substances, wherein said porous polymer is a particulate material, with particles having an average diameter in the range of approximately 0.1 microns to approximately 0.5 centimeters, and having a plurality of pores with an average pore diameter in a range of approximately 50 Angstroms to approximately 40,000 Angstroms.